Key terms
About DBVT
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DBVT news
Yesterday
4:52pm ET
DBV Technologies SA Announces ADS Ratio Adjustment and Market Strategy
May 08
6:14am ET
DBV Technologies price target lowered to $5 from $10 at H.C. Wainwright
May 07
4:53pm ET
DBV Technologies reports Q1 EPS (28c), consensus (15c)
Mar 08
4:24pm ET
DBV Technologies Announces Completion of Annual Report
Mar 08
6:29am ET
Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes
Mar 08
12:26am ET
Positive Clinical and Financial Projections for DBV Technologies Reinforce Buy Rating
Feb 26
12:25am ET
Buy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising Trials
Feb 20
12:45am ET
JMP Securities Keeps Their Buy Rating on DBV Technologies SA – American (DBVT)
No recent press releases are available for DBVT
DBVT Financials
Key terms
Ad Feedback
DBVT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DBVT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range